Skip to content
HowShorted

INTERCEPT PHARMACEUTICALS, INC. short interest in 2018

In 2018, INTERCEPT PHARMACEUTICALS, INC.'s disclosed short interest ran from 21.65% of shares outstanding on 12 Jan 2018 to 10.23% on 31 Dec 2018, a change of -11.42 percentage points. The year's high was 27.87% on 29 Mar 2018 and its low 9.72% on 14 Dec 2018, averaging 17.57% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.80 days on 29 Mar 2018. Full history: INTERCEPT PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023

Aggregate net short position time series for INTERCEPT PHARMACEUTICALS, INC. in 2018

2018 in figures

Start of year
21.65% (12 Jan 2018)
End of year
10.23% (31 Dec 2018)
Change
-11.42 pp
High
27.87% (29 Mar 2018)
Low
9.72% (14 Dec 2018)
Average
17.57%
Highest days to cover
14.80 (29 Mar 2018)
SEC filings marked
8

Every report in 2018

INTERCEPT PHARMACEUTICALS, INC. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201821.65%5.73
31 Jan 201821.96%5.47
15 Feb 201826.90%5.00results (8-K)
28 Feb 201827.28%12.3110-K filed
15 Mar 201827.47%10.60
29 Mar 201827.87%14.80
13 Apr 201823.49%4.11
30 Apr 201819.73%7.64
15 May 201820.07%11.90results (8-K), 10-Q filed
31 May 201818.17%9.22
15 Jun 201819.81%6.63
29 Jun 201821.17%6.14
13 Jul 201817.83%9.56
31 Jul 201816.24%10.42
15 Aug 201813.54%4.53results (8-K), 10-Q filed
31 Aug 201812.79%13.00
14 Sep 201812.44%12.02
28 Sep 201811.26%7.19
15 Oct 201810.46%6.03
31 Oct 201810.41%5.91results (8-K)
15 Nov 201810.71%6.5210-Q filed
30 Nov 201810.36%8.29
14 Dec 20189.72%7.43
31 Dec 201810.23%6.26

See also: INTERCEPT PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.